Premium
INDORAMIN AND HYPERTENSION: CLINICAL STUDIES
Author(s) -
ROSENDORFF CLIVE
Publication year - 1981
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1981.tb00301.x
Subject(s) - supine position , medicine , blood pressure , heart rate , essential hypertension , anesthesia , crossover study , cardiology , placebo , alternative medicine , pathology
1 An open clinical trial of indoramin, a new antihypertensive agent with α‐adrenoreceptor blocking properties, in 27 patients with mild to moderate hypertension, showed good blood pressure reduction, no significant change in heart rate, and only mild side‐effects. 2 A comparison of indoramin and methyldopa in the treatment of mild and moderate essential hypertension in 31 middle‐aged patients was made by means of a double‐blind crossover trial. 3 Satisfactory control of systolic and diastolic blood pressure, in the standing and supine positions, was achieved by both drugs. With a mean dose of 158 ± 9 mg per day of indoramin the average fall in supine and standing blood pressures was 16/6 and 16/8 mm Hg respectively. Equivalent values for methyldopa, with a mean dose of 1 540 ± 90 mg per day, were 21/8 and 26/13 mm Hg. Values for the two drugs are not significantly different. 4 There were no significant differences between the two drugs in their effect on the heart rate or in the incidence of side‐effects.